More so now than ever, the inclusion of more diverse, and often more relevant, study populations is gathering momentum within the clinical trial community.
Biomarkers have been causing a paradigm shift in how HCPs treat patients for some time – now they are bringing the pharma industry a new gold standard for clinical research.
Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological era for medicines.
The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.